Press Releases

BeiGene, Ltd.  Ltd. today announced that the China National Medical Products Administration  has approved SYLVANT for the treatment of adult patients with multicentric Castleman disease  who are human immunodeficiency virus  negative and human herpes virus-8  negative, also known as idiopathic MCD . This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues. Siltuximab is a monoclonal antibody approved in the Unite

Silo Pharma, Inc.  a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore licensed homing peptide.  The novel homing peptide can be used for enhanced targeting of therapeutic agents to the central nervous system. Silo Pharma’s licensed homing peptide can potentially improve pharmacological treatment of disease, lower effective dosages, thereby reducing si

Adare Pharma Solutions , une organisation mondiale de recherche, de développement et de fabrication sous contrat (CDMO), axée sur la technologie, a annoncé aujourd'hui l'acquisition de Frontida BioPharm (« Frontida »), une CDMO intégrée verticalement, axée sur les formulations orales. L'acquisition renforce l'engagement d'Adare à transformer la livraison des médicaments en fournissant des solutions de clas

Astellas Pharma Inc.  and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create no

aTyr Pharma, Inc.  a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, today announced a manufacturing agreement for ATYR1923, aTyr Pharma’s lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of i

PharmaCyte Biotech, Inc. a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study to determine if the treatment PharmaCyte uses for locally advanced, inoperable pancreatic cancer Cell-in-a-Box (CypCaps™) combined with the cancer killing prodrug ifosfamide can also delay the rate of production and accumulation of malignant as

Todos Medical, Ltd.  a comprehensive medical diagnostics and related solutions company, today announced it has entered into a binding agreement to acquire all 3CL protease biology-related assets owned by NLC Pharma and form a majority-owned subsidiary called 3CL Sciences (“3CL Sciences”). 3CL Sciences will be focused on developing therapeutics, diagnostics and dietary supplements based on the pioneering 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology work of Dorit Ar

Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award. The stock option has an exercise price of $0.59 share, which is equal to the closing price of Zosano’s common stock on November 29, 2021. 25% of the shares underlying the option will vest on November 29, 2022, and 1/48th of the total shares w

With the emergence in South Africa of yet another potentially more dangerous COVID-19 strain, AIDS Healthcare Foundation (AHF) echoes President Biden’s recent appeal for wealthy countries to step up the sharing of their excess vaccines and to back patent waivers and technology transfers that can boost global vaccine production. “The new variant proves that hoarding vaccines is suicidal. While rich countries try to quarantine themselves from the rest of the world, new str

QIAGEN NV  announced today that the company's polymerase chain reaction (PCR) -based tests In view of the new, worrying variant that was discovered in South Africa, effectively detect SARS-CoV-2 infections without restrictions. QIAGEN has successfully checked its SARS-CoV-2 PCR tests for the genetic mutations of the variant with the scientific name B.1.1.529. The assessment was carried out using the data available in the public databases GISAID and GenBank.